Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty

European Heart Journal

Volumn 23, Issue 9, 2002, Pages 726-733

  Schnyder, Guido ^a,b   Roffi, M ^a   Flammer, Y ^a   Pin, R ^a   Hess, O M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Death; Homocysteine; Myocardial infarction; Restenosis

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; STATISTICS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036558642     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2962     Document Type: Article

References (32)

1. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-71.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
3. Tardif JC, Cote G, Lesperance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-72.
4. Tsuchikane E, Fukuhara A, Kobayashi T et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100: 21-6.
5. Kiesz RS, Buszman P, Martin JL et al. Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). Circulation 2001; 103: 26-31.
6. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
7. Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am 2000; 84: 215-37.
8. Chao CL, Tsai HH, Lee CM et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 1999; 147: 379-86.
9. Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol 2001; 88: 7-10.
10. Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
11. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-73.
12. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-81.
13. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
14. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
15. Wang XL, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146: 133-40.
16. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998; 98: 196-9.
17. Ubbink JB, Hayward-Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-6.
18. Genest JJ Jr, McNamara JR, Upson B et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11: 1129-36.
19. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998; 98: 2520-6.
20. Miner SE, Hegele RA, Sparkes J et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study. Am Heart J 2000; 140: 272-8.
21. Morita H, Kurihara H, Kuwaki T et al. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb Haemost 2000; 84: 27-31.
22. Rodgers GM, Kane WH, Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
23. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
24. Hajjar KA, Mauri L, Jacovina AT et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-93.
25. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-33.
26. Hirshfeld JW Jr, Schwartz JS, Jugo R et al. Restenosis after coronary angioplasty: A multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991; 18: 647-56.
27. Erbel R, Haude M, Hopp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N Engl J Med 1998; 339: 1672-8.
28. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-27.
29. Briguori C, Nishida T, Adamian M et al. Coronary stenting versus balloon angioplasty in small coronary artery with complex lesions. Catheter Cardiovasc Interv 2000; 50: 390-7.
30. Teirstein PS, Massullo V, Jani S et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697-703.
31. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996; 77: 759-61.
32. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998; 316: 894-8.